ArticlePloS one2025
Clinical and quality of life improvement after bilastine treatment among patients with autoimmune chronic spontaneous urticaria.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the clinical effectiveness of bilastine in type IIb autoimmune CSU (type IIb aiCSU) patients over an 8-week period, as well as to identify factors predicting treatment response.
method34 type IIb aiCSU patients with positive basophil histamine release assays (BHRA) and positive Autologous Serum Skin Test (ASST) tests, from the Vietnam National Dermatology and Venereology Hospital, were included. Patients began treatment with the standard dose of bilastine, with the dose increased every two weeks for those who did not achieve adequate response. The Urticaria Control Test (UCT), Weekly Urticaria Activity Score (UAS7), and the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) were used.
resultsSignificant improvements in all measures were observed, with 82.4% of patients achieving complete response by week 8. Of these, 47.1% responded to the standard dose, while 14.7% did not respond even at the maximum (x4) dose. UAS7 average scores decreased from a baseline mean of 28.9 to 2.9, indicating substantial reduction in disease activity. UCT scores improved from 47.1% of patients having poor disease control (UCT < 12) after week 2 to 85.3% achieving good control (UCT ≥ 12) by week 8. QoL also significantly improved, with CU-Q2oL scores dropping from 44.9 at baseline to 25.3 at week 8. Basopenia, high baseline UAS7 score and a history of autoimmune disease were associated with poorer treatment responses, while normal/high IgE levels were linked to better outcomes.
conclusionThe findings suggest that bilastine is highly effective in controlling aiCSU symptoms and improving QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.